Alexion Pharmaceuticals, Inc. has announced the appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to the Company’s Board of Directors.

Mr. Brennan, 60, most recently served as Chief Executive Officer and Executive Director of AstraZeneca PLC. Ms. Burns, 56, currently serves as Center Fellow and Strategic Advisor, Stanford University Center on Longevity. Mr. Coughlin, 62, is currently a Senior Advisor, McKinsey & Co., where he has served since 2012.

“David, Michele and Chris bring significant commercial, financial, risk management and operational expertise to the Board. Their expertise and experience will be valuable to our growing business and we are pleased to welcome them,” said Max Link, Ph.D., Chairman of Alexion’s Board of Directors.